What's in Alzheon Inc.'s pipeline?

Alzheon Inc. has 2 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Alzheon Inc.'s portfolio?

Top competitors by shared drug class: AC Immune SA, Tanabe Pharma Corporation.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/alzheon-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Alzheon Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Alzheon Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Experimental: ALZ-801	Experimental: ALZ-801	phase 3	Tau aggregation inhibitor	Tau protein	Neurology

Therapeutic area mix

Neurology · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AC Immune SA · 1 shared drug class
Tanabe Pharma Corporation · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Alzheon Inc.:

Cite this brief

Drug Landscape (2026). Alzheon Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/alzheon-inc. Accessed 2026-06-10.